Veru Inc

NASDAQ:VERUUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Contact Information

Headquarters

2916 N. MIAMI AVENUE, SUITE 1000MIAMI, FL, United States 33127

Phone

312-595-9123

Fax

312-595-9122

Executives

Chairman of the Board, President, Chief Executive Officer

Mitchell Steiner

Chief Corporate Officer, Director

Harry Fisch

Chief Financial Officer, Chief Administrative Officer

Michele Greco

Chief Scientific Officer

K. Gary Barnette

Independent Director

Mario Eisenberger